Drug Trial Radar · NCT05526313
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant
Last checked: Nov 20, 2026Latest source record: Oct 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Aug 10, 2020
Primary completion
Sep 7, 2022
Study completion Mar 29, 2024
Sponsor
- Lead sponsor
- Chengdu Zenitar Biomedical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Purinostat mesylate for injection (PM) was the novel and highly potent Class I a and IIb HDAC-selective inhibitors. The results of regular blood sampling analysis of the mouse B-cell lymphoma model induced by ighmyc transgenic mice showed that the treatment of PM in each group reduced the proportion of peripheral blood tumor cells in mice. Therefore, PM has the potential to treat diffuse large B cell lymphoma. The results of in vitro enzymatic activity screening showed that PM has high inhibitory activity on HDAC tumors (including HDAC1, 2, 3, 8 subtypes) and type II HDACs (including HDAC6, 10 isoforms), which are closely related to tumors in the HDAC family. Therefore, the results of in vitro enzyme activity screening showed that the IC50 values of PM for inhibiting HDAC1, HDAC2, HDAC3, HDAC8, HDAC6, and HDAC10 subtypes of HDAC class I and HDAC class IIb were 0.81, 1.4, 1.7, 3.8, 11.5, and 11 nM, respectively. However, the inhibitory activity of HDAC IIa and HDAC IV enzymes was low, and its IC50 values for HDAC4, HDAC5, HDAC7, HDAC9, and HDAC11 subtypes of HDAC IIa and HDAC IV were 1072, 426, 590, 622, and 3349 nM, respectively. These data means PM exist high selectivity for tumor-associated HDAC class I and HDAC IIb. Compared with the blank control group, the body weight of the tumor-bearing animals in each dose of PM group did not decrease seriously during the treatment process, and the animals were in good condition during the whole experiment, indicating that the PM is efficacy and safe. During the course of the experiment, the tumor cell population (GFP+, B220+) in the blood of the animals basically regressed after treatment with Prilistat hydrochloride. Research purposes: Main purpose: Observation of patients with relapsed or refractory hematological tumors (including but not limited to after standard therapy) mainly in patients with relapsed or refractory B cell-related tumors. Tolerability and safety of B-cell lymphoma, multiple myeloma, B-cell acute leukemia, T-cell lymphoma, T-cell acute leukemia) with disease progression or ineligible for standard therapy. To observe the dose-limiting toxicity (DLT) in patients with relapsed or refractory B cell-related tumors and hematological tumors, and determine its maximum tolerated dose (MTD), which is the maximum tolerated dose (MTD). Phase II clinical dosing schedule provides the basis. Secondary Purpose: To evaluate the pharmacokinetic parameters of patients with relapsed or refractory B-cell-related tumors and hematological tumors after single and multiple intravenous infusions of priinostat mesylate for injection. To evaluate the pharmacodynamics of patients with relapsed or refractory B cell-related tumors and hematological tumors after single and multiple intravenous infusions of priinostat mesylate for injection. To preliminarily observe the efficacy of Priinostat mesylate for injection in the treatment of patients with relapsed or refractory hematological tumors, mainly patients with B cell-related tumors.
Conditions
- Diffuse Large B Cell Lymphoma,DLBCL
Interventions
Purinostat Mesylate 1.2mg/m^2Drug
1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.
Purinostat Mesylate 2.4mg/m^2Drug
Take the medicine once on D1, D8, D11, D15.
Purinostat Mesylate 4.0mg/m^2Drug
Take the medicine once on D1, D8, D11, D15.
Purinostat Mesylate 6.0mg/m^2Drug
Take the medicine once on D1, D8, D11, D15.
Purinostat Mesylate 8.4mg/m^2Drug
Take the medicine once on D1, D8, D11, D15.
Purinostat Mesylate 11.2mg/m^2Drug
Take the medicine once on D1, D8, D11, D15.
Purinostat Mesylate 15mg/m^2Drug
Take the medicine once on D1, D8, D11, D15.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Purinostat Mesylate Pharmacokinetics (PK):CmaxTime frame: 72hours
- Purinostat Mesylate Pharmacokinetics (PK):TmaxTime frame: 72hours
- Purinostat Mesylate Pharmacokinetics (PK):AUC0-72hTime frame: 72hours
- Purinostat Mesylate Pharmacokinetics (PK):AUC0-∞Time frame: 72hours
- Purinostat Mesylate Pharmacokinetics (PK):MRTTime frame: 72hours
- Purinostat Mesylate Pharmacokinetics (PK):VdTime frame: 72hours
- Purinostat Mesylate Pharmacokinetics (PK):t1/2Time frame: 72hours
- Purinostat Mesylate Pharmacokinetics (PK):CLz/FTime frame: 72hours
- Purinostat Mesylate Pharmacokinetics (PK):Vz/FTime frame: 72hours
- Purinostat Mesylate Pharmacokinetics (PK):KeTime frame: 72hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.